Published in Neuropsychiatr Dis Treat on April 03, 2013
An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation. Tob Control (2014) 1.63
Executive dysfunction in children affected by obstructive sleep apnea syndrome: an observational study. Neuropsychiatr Dis Treat (2013) 1.09
Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction. BMC Public Health (2016) 0.82
A preliminary study of the influence of age of onset and childhood trauma on cortical thickness in major depressive disorder. Biomed Res Int (2014) 0.80
Reward processing deficits and impulsivity in high-risk offspring of alcoholics: A study of event-related potentials during a monetary gambling task. Int J Psychophysiol (2015) 0.77
What Can Rats Tell Us about Adolescent Cannabis Exposure? Insights from Preclinical Research. Can J Psychiatry (2016) 0.76
Adolescent caffeine consumption increases adulthood anxiety-related behavior and modifies neuroendocrine signaling. Psychoneuroendocrinology (2016) 0.76
Sensitive periods of substance abuse: Early risk for the transition to dependence. Dev Cogn Neurosci (2016) 0.76
In utero exposure to valproic acid changes sleep in juvenile rats: a model for sleep disturbances in autism. Sleep (2014) 0.75
Cannabis and alcohol use, and the developing brain. Behav Brain Res (2017) 0.75
Adolescent Mice Are Resilient to Alcohol Withdrawal-Induced Anxiety and Changes in Indices of Glutamate Function within the Nucleus Accumbens. Front Cell Neurosci (2016) 0.75
Early life adversity: Lasting consequences for emotional learning. Neurobiol Stress (2016) 0.75
New Implications for the Melanocortin System in Alcohol Drinking Behavior in Adolescents: The Glial Dysfunction Hypothesis. Front Cell Neurosci (2017) 0.75
A family-oriented treatment program for youths with ketamine abuse and their caregivers: a pilot study in Taiwan. Neuropsychiatr Dis Treat (2015) 0.75
Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci (1999) 18.57
The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev (2000) 17.59
A Social Neuroscience Perspective on Adolescent Risk-Taking. Dev Rev (2008) 9.52
Structural magnetic resonance imaging of the adolescent brain. Ann N Y Acad Sci (2004) 6.13
Peer influence on risk taking, risk preference, and risky decision making in adolescence and adulthood: an experimental study. Dev Psychol (2005) 6.04
The case for motivated reasoning. Psychol Bull (1990) 5.76
Cognitive and affective development in adolescence. Trends Cogn Sci (2005) 5.50
The emergence of gender differences in depression during adolescence. Psychol Bull (1994) 5.12
The adolescent brain. Ann N Y Acad Sci (2008) 4.66
Risk taking in adolescence: what changes, and why? Ann N Y Acad Sci (2004) 4.33
The neural basis of puberty and adolescence. Nat Neurosci (2004) 3.68
Neurocognitive functioning of adolescents: effects of protracted alcohol use. Alcohol Clin Exp Res (2000) 3.16
Sexual and reproductive health of persons aged 10-24 years - United States, 2002-2007. MMWR Surveill Summ (2009) 2.89
Sex differences in the adolescent brain. Brain Cogn (2009) 2.20
Developmental epidemiology of drug use and abuse in adolescence and young adulthood: Evidence of generalized risk. Drug Alcohol Depend (2009) 1.84
Probing the neural correlates of anticipated peer evaluation in adolescence. Child Dev (2009) 1.82
Gender differences in factors influencing alcohol use and drinking progression among adolescents. Clin Psychol Rev (2009) 1.75
Social cognitive development during adolescence. Soc Cogn Affect Neurosci (2006) 1.46
Developmental changes in dopamine neurotransmission in adolescence: behavioral implications and issues in assessment. Brain Cogn (2009) 1.44
Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol (2010) 1.31
The emergence of gonadal hormone influences on dopaminergic function during puberty. Horm Behav (2009) 1.31
A psychobiological framework of the substrates that mediate nicotine use during adolescence. Neuropharmacology (2008) 1.29
Functional magnetic resonance imaging of facial affect recognition in children and adolescents. J Am Acad Child Adolesc Psychiatry (1999) 1.27
Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol (2011) 1.21
Puberty, hormones, and sex differences in alcohol abuse and dependence. Neurotoxicol Teratol (2006) 1.20
Development of the social brain in adolescence. J R Soc Med (2012) 1.10
Sex steroids and connectivity in the human brain: a review of neuroimaging studies. Psychoneuroendocrinology (2011) 1.10
Adolescent ethanol exposure: does it produce long-lasting electrophysiological effects? Alcohol (2010) 1.04
Immediate and prolonged effects of alcohol exposure on the activity of the hypothalamic-pituitary-adrenal axis in adult and adolescent rats. Brain Behav Immun (2011) 0.97
Behavioral and neural representation of emotional facial expressions across the lifespan. Dev Neuropsychol (2011) 0.96
Developmental differences in the accumbal dopaminergic response to repeated ethanol exposure. Ann N Y Acad Sci (2004) 0.95
Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr (2012) 0.93
The role and the mechanism of gamma-aminobutyric acid during central nervous system development. Neurosci Bull (2008) 0.91
Development of eating behavior: biology and context. J Dev Behav Pediatr (2012) 0.90
Side effects of oncologic therapies in the pediatric central nervous system: update on neuroimaging findings. Radiographics (2011) 0.86
Adolescent neurological development and its implications for adolescent substance use prevention. J Prim Prev (2008) 0.85
Reconceptualizing in a dual-system model the effects of prenatal cocaine exposure on adolescent development: a short review. Int J Dev Neurosci (2011) 0.84
Long-term effects of adolescent-onset and persistent use of cannabis. Proc Natl Acad Sci U S A (2012) 0.83
Effects of exogenous agents on brain development: stress, abuse and therapeutic compounds. CNS Neurosci Ther (2010) 0.78
From superior adaptation and function to brain dysfunction--the neglect of epigenetic factors. Nutr Health (2004) 0.77
Under construction: Brain formation, culpability, and the criminal justice system. Int J Law Psychiatry (2011) 0.77
Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cereb Blood Flow Metab (2009) 1.80
Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. J Neurosci Res (2011) 1.24
Adult Spinal Cord Injury without Radiographic Abnormalities (SCIWORA): Clinical and Radiological Correlations. J Clin Med Res (2009) 0.98
Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci (2006) 0.90
Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin or bengamides. Cancer Res (2004) 0.86
Congenital Insensitivity to Pain with Anhidrosis (HSAN Type IV), Extremely Rare Syndrome that Can Be Easily Missed by Bone and Joint Surgeons: A Case Report. Iran J Pediatr (2012) 0.84
Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets (2006) 0.84
Effect of diet on serotonergic neurotransmission in depression. Neurochem Int (2013) 0.82
Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease. Proc West Pharmacol Soc (2002) 0.81
Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. Exp Biol Med (Maywood) (2006) 0.81
Clinical significance of metallothioneins in cell therapy and nanomedicine. Int J Nanomedicine (2013) 0.79
The multiple actions of selegiline. Proc West Pharmacol Soc (2002) 0.77
Boceprevir: A new hope against hepatitis C virus. J Pharmacol Pharmacother (2012) 0.75
An adverse drug reaction clinic: Breathing fresh life into the pharmacovigilance programme. J Pharmacol Pharmacother (2012) 0.75
Rare presentation of bilateral femoral arteriovenous fistula. Asian Cardiovasc Thorac Ann (2008) 0.75